



PHARMACY POLICY STATEMENT North Carolina Marketplace

DRUG NAME	Spevigo (spesolimab -sbzo)
BILLING CODE	J3590
BENEFIT TYPE	Medical
STATUS	Prior Authorization Required

Spevigo is an interleukin-36 receptor antagonist initially approved by the FDA in 2022. It is the first treatment specifically approved for Generalized Pustular Psoriasis flares and the first IL-36 receptor antagonist to be approved. GPP is a rare, potentially life-threatening neutrophilic skin condition, and individuals with GPP typically experience episodes of widespread eruptions of painful, sterile pustules. While the severity of GPP flares can vary, if left untreated they can be life-threatening due to complications such as sepsis and multisystem organ failure. A preceding history of plaque psoriasis may or may not be present in individuals presenting with GPP. Spevigo was studied in the Effisayil-1 trial, a randomized, double-blind, nd pres[.8 (ed, boJ 0 Tc (-)Tj 0.001 Tc [(b)lc7 (o)5.)0.7 (eato1 (l)-1.1 (y)3the).7 (i)-1 (al)4



For reauthorization :
Medication will not be authorized for continuous use.

CareSource considers Spevigo (spesolimab -sbzo) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off- Label policy.

DATE	ACTION/DESCRIPTION
09/21/2022	New policy for Spevigo created.

References:

1. Spevigo [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; September 2022.
2. Bachelez H, Choon SE, Marrakchi S, et al; for the Effisayil 1 Trial Investigators. Trial of spesolimab for generalized pustular psoriasis. *N Engl J Med.* 2021;385(26):2431-2440.
3. Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. *J Eur Acad Dermatol Venereol* 2017;31:1792-9.
4. Hoegler KM, John AM, Handler MZ, Schwartz RA. Generalized pustular psoriasis: a review and update on treatment. *J Eur Acad Dermatol Venereol.* 2018 Oct;32(10):1645-1651.

Effective date: 04/01/2023
Revised date: 09/21/2022